Anogen

Anogen-Yes Biotech Laboratories Ltd., established in 1989 and headquartered in Mississauga, Canada, is a distinguished provider of high-quality antibody-based products for research, diagnostic, and therapeutic applications. The company offers an extensive portfolio of over 300 monoclonal and polyclonal antibodies, as well as more than 60 types of ELISA kits, serving the global biotechnology, pharmaceutical, and academic research communities.

As a research-driven organization, Anogen has developed a range of proprietary products, including Abcream, a topical anti-IL-8 monoclonal antibody treatment for psoriasis, which received approval from the State Food and Drug Administration (SFDA) of China in 2001. Anogen also conducts ongoing research in key therapeutic areas, including inflammation, Alzheimer's disease, and cancer, reflecting its commitment to advancing biomedical sciences.

Anogen’s adherence to rigorous quality standards is underscored by its ISO 13485:2016 certification, ensuring the highest level of quality in every antibody and ELISA kit delivered. With an in-house cell bank containing over 1,000 hybridomas, Anogen maintains complete control over the antibody production process, providing researchers and clinical laboratories with products that meet the highest scientific and regulatory standards.

The company focuses on meeting the growing need for antibodies in proteomics, providing essential tools for both diagnostic and therapeutic applications. Its products support the development of targeted treatments for autoimmune, inflammatory, and cardiovascular diseases. With ongoing innovations in antibody development, Anogen plays a vital role in advancing medical research and improving global healthcare.